## Abstract Six patients with fluctuating Parkinson's disease received single rising oral doses of the nonergot dopamine agonist CV 205‐502 in an open experimental study. Doses of 0.5 mg produced antiparkinsonian effects of comparable intensity but longer duration than 200 mg of L‐DOPA. CV 205‐502,
Disappearance of a pituitary tumor after 15 months of treatment with CV 205–502, a new dopamine agonist
✍ Scribed by Faβbender, W. J. ;Stracke, H. ;Bachmann, G. ;Rau, W. ;Federlin, K.
- Publisher
- Springer-Verlag
- Year
- 1992
- Tongue
- English
- Weight
- 482 KB
- Volume
- 70
- Category
- Article
- ISSN
- 1432-1440
No coin nor oath required. For personal study only.
✦ Synopsis
We report the case of a 27-year-old woman with a prolactin-secreting macroadenoma of the pituitary gland who was under treatment with a new dopamine agonist, Sandoz CV 205-502. Immediately after diagnosis of a 12 x 10 mm intrasellar prolactinoma, treatment with CV 205-502 was begun at a daily dose of 0.075 mg. Under this low dose, prolactin in the serum normalized after 4 weeks, the initial hormone value being 189.9 ng/ml. After 6 months of therapy there was still a 6 x 6 mm tumor, and after 15 months of treatment the pathological process could no longer be observed with magnetic resonance imaging. In the 20th month of therapy the patient became pregnant. An ovulatory menstrual cycle had been present for a few months.
📜 SIMILAR VOLUMES